[Cooperation Agreement on Transfer of Source Plasma and Plasma Ingredients I+II+III Sediments for Producing Blood Products This Agreement is entered into in the city of Beijing on September 30, 2014 by and between: Party A (Supplier): Xinjiang Deyuan Bioengineering Co., Ltd. Party B (Receiver): Guizhou Taibang Biological Products Co., Ltd. WHEREAS: PRC 1. Both parties are established in good standing] [Supplemental Agreement to Cooperation Agreement on Transfer of Source Plasma and Plasma Ingredients I+II+III Sediments for Producing Blood Products This Supplemental Agreement is entered into on April 16, 2015 by and between: Party A (Supplier): Xinjiang Deyuan Bioengineering Co., Ltd; Party B (Receiver): Guizhou Taibang Biological Products Co., Ltd Any term not otherwise defined herein shall have the meaning ascribed] [FOR RELEASE April 16, 2015 China Biologic Receives Approval to Purchase Raw Materials BEIJING, China – April 16, 2015 – These raw materials are expected to be delivered during the second quarter of 2015, and the final purchase volume is contingent upon the Company's quality inspection of these raw materials. The Company expects that the final products made from such] []

[CHINA BIOLOGIC PRODUCTS, INC. DIRECTOR AGREEMENT Agreement Company Mr. Min Fang Director THIS AGREEMENT (The “ BACKGROUND The Board of Directors of the Company desires to appoint the Director to fill an existing vacancy due to resignation of Mr. Dai Feng and to have the Director perform the duties of a director and the Director desires to be so appointed] [FOR RELEASE March 4, 2015 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4Q14 Total Sales Up 36.2% to 58.0 Million / FY14 Total Sales Up 19.6% to $243.3 Million -- -- -- 4Q14 Operating Margin Up 470 Basis Points to 34.0% / FY14 Operating Margin Up 300 Basis Points to 45.7% -- -- 4Q14] []

[Annual Report on Form 10-K Year Ended December 31, 2014 TABLE OF CONTENTS PART I Item 1. Business 3 Item 1A. Risk Factors 22 Item 1B. Unresolved Staff Comments 44 Item 2. Properties 44 Item 3. Legal Proceedings 45 Item 4. Mine Safety Disclosures 47 PART II Item 5. 48 Item 6. Selected Financial Data 49 Item 7. Management’s Discussion] [23.1 Consent of Independent Registered Public Accounting Firm The Board of Directors China Biologic Products, Inc.: We consent to the incorporation by reference in registration statements (No. 333-171069, 333-182624 and 333-196591) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated March 4, 2015, with respect to the consolidated] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial and Accounting Officer)]